Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy

Table 5

Multivariate Cox regression. In the multivariate Cox regression no other covariate than mutated KRAS significantly improved the model.

Model number	Covariates	Number of patients	Hazard ratio (HR)	𝑃	95% confidence interval
	Kras
	Not mutated	45	1.00
(1)	Mutated	19	2.32	0.010	1.21–4.13
	Stage
	IIIa	16	1.00
	IIIb	48	1.60	0.21	0.76–3.34
	Kras
	Not mutated	47	1.00
(2)	Mutated	19	2.32	0.005	1.30–4.44
	PS
	0	34	1.00
	1	32	1.42	0.23	0.80–2.51
	Kras
	Not mutated	47	1.00
(3)	Mutated	19	2.32	0.005	1.30–4.44
	Weight loss
	Continues (kg)	66	1.05	0.30	0.95–1.15
	Kras
	Not mutated	47	1.00
(4)	Mutated	19	2.28	0.008	1.24–4.20
	Sex
	Males	38
	Females	31	0.63	0.132	0.35–1.15
	Kras
	Not mutated	47	1.00
(5)	Mutated	19	2.28	0.007	1.27–4.27
	Age
	Continues (year)	66	0.99	0.524	0.95–1.03
	Kras
	Not mutated	47	1.00
(6)	Mutated	19	2.32	0.007	1.26–4.26
	Study
	RAKET	32	1.00	0.77	0.52–1.63
	Satellite	34	0.92